| Literature DB >> 34234163 |
Amy A Kirkham1,2, Mark J Haykowsky3, Rhys I Beaudry2, Justin G Grenier2, John R Mackey2, Edith Pituskin3, D Ian Paterson2, Richard B Thompson4.
Abstract
This study aimed to characterize peak exercise cardiac function and thigh muscle fatty infiltration and their relationships with VO2peak among anthracycline-treated breast cancer survivors (BCS). BCS who received anthracycline chemotherapy ~ 1 year earlier (n = 16) and matched controls (matched-CON, n = 16) were enrolled. Resting and peak exercise cardiac function, myocardial T1 mapping (marker of fibrosis), and thigh muscle fat infiltration were assessed by magnetic resonance imaging, and VO2peak by cycle test. Compared to matched-CON, BCS had lower peak SV (64 ± 9 vs 57 ± 10 mL/m2, p = 0.038), GLS (- 30.4 ± 2.2 vs - 28.0 ± 2.5%, p = 0.008), and arteriovenous oxygen difference (16.4 ± 3.6 vs 15.2 ± 3.9 mL/100 mL, p = 0.054). Mediation analysis showed: (1) greater myocardial T1 time (fibrosis) is inversely related to cardiac output and end-systolic volume exercise reserve; (2) greater thigh muscle fatty infiltration is inversely related to arteriovenous oxygen difference; both of which negatively influence VO2peak. Peak SV (R2 = 65%) and thigh muscle fat fraction (R2 = 68%) were similarly strong independent predictors of VO2peak in BCS and matched-CON combined. Post-anthracyclines, myocardial fibrosis is associated with impaired cardiac reserve, and thigh muscle fatty infiltration is associated with impaired oxygen extraction, which both contribute to VO2peak.Entities:
Year: 2021 PMID: 34234163 PMCID: PMC8263737 DOI: 10.1038/s41598-021-93241-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Representative participants with low, medium, and high thigh fat fraction with their respective water and fat suppressed images used to delineate the fat and muscle components. Axial right thigh images were acquired by magnetic resonance imaging and 40 cm of volume were analyzed starting 110 mm from the distal point of the femur to quantify absolute volumes of muscle and intermuscular fat (IMF). The thigh fat fraction was then calculated as: IMF/(IMF + muscle)*100%. Thigh fat fraction was inversely associated with VO2peak in both breast cancer survivors and matched controls.
Participant descriptive data.
| Variable | Young controls (n = 12) | Matched controls (n = 16) | Breast cancer survivors (n = 16) | p-value |
|---|---|---|---|---|
| Age (years, mean ± SD) | 25 ± 4 | 56 ± 10* | 56 ± 10* | |
| Body mass index (kg/m2, mean ± SD) | 22 ± 2 | 28 ± 5* | 29 ± 4* | |
| Body surface area (m2, mean ± SD) | 1.68 ± 0.10 | 1.84 ± 0.15* | 1.84 ± 0.18* | |
| Caucasian (n (%)) | 12 (100%) | 16 (100%) | 15 (94%) | 1.00 |
*Statistically different from young controls at p ≤ 0.01.
P-value shown for comparison between matched controls and survivors only as young controls lacked all of these risk factors by default.
‡Of the two breast cancer group participants reporting a history of hypertension, only one was currently on medication (a calcium channel blocker) and she reported not taking it during anthracycline therapy or on the day of the assessment.
Figure 2Change and mean cardiac function from rest to peak exercise among anthracycline-treated breast cancer survivors (n = 16), age- and body mass index-matched non-cancer controls (n = 16), and young, healthy controls (n = 12). All data is derived from cardiac magnetic resonance imaging. Volumes are normalized to body surface area. Young controls had larger peak and reserve stroke volume and cardiac output compared to both other groups. Compared to matched controls, breast cancer survivors had lower rest and exercise stroke volume and global longitudinal strain, and cardiac output reserve. *Difference from both breast cancer survivors and matched control groups at p ≤ 0.05; Difference from matched control group at p ≤ 0.05; ‡Difference from breast cancer survivor group at p ≤ 0.05;
Cardiac magnetic resonance and cardiopulmonary data.
| Variable | Young controls (n = 12) (mean ± SD) | Matched controls (n = 16) (mean ± SD) | Breast cancer survivors (n = 16) (mean ± SD) | P-value |
|---|---|---|---|---|
| Heart rate (bpm) | 74 Ü9 | 64 ± 11* | 68 ± 10 | |
| End-diastolic volume index (mL/m2) | 94 ± 15 | 80 ± 10* | 75 ± 12* | |
| End-systolic volume index (mL/m2) | 34 ± 7 | 26 ± 4* | 26 ± 4* | |
| Stroke volume index (mL/m2) | 61 ± 10 | 54 ± 7* | 49 ± 9*† | |
| Ejection fraction (%) | 64 ± 3 | 67 ± 4 | 65 ± 3 | 0.123 |
| Cardiac output index (L/min/m2) | 4.5 ± 0.8 | 3.4 ± 0.6* | 3.3 ± 0.5* | |
| Global longitudinal strain (%) | − 24.4 ± 1.4 | − 25.4 ± 2.4 | − 23.4 ± 2.2† | |
| Supine stepper power output (watts) | 255 + 25 | 151 ± 29* | 122 ± 30*† | |
| Heart rate (bpm) | 155 ± 22 | 140 ± 17 | 140 ± 17 | 0.067 |
| End-diastolic volume index (mL/m2) | 97 ± 15 | 85 ± 11* | 77 ± 12* | |
| End-systolic volume index (mL/m2) | 23 ± 6 | 21 ± 5 | 20 ± 4 | 0.448 |
| Stroke volume index (mL/m2) | 75 ± 11 | 64 ± 9* | 57 ± 10*† | |
| Ejection fraction (%) | 77 ± 4 | 76 ± 4 | 73 ± 4 | 0.071 |
| Cardiac output index (L/min/m2) | 11.1 ± 2.2 | 9.0 ± 1.7* | 8.0 ± 2.0* | |
| Global longitudinal strain (%) | − 31.8 ± 3.0 | − 30.4 ± 2.2 | − 28.0 ± 2.5*† | |
| Heart rate (bpm) | 81 ± 19 | 76 ± 12 | 72 ± 20 | 0.394 |
| End-diastolic volume index (mL/m2) | 3 ± 3 | 5 ± 5 | 2 ± 6 | 0.312 |
| End-systolic volume index (mL/m2) | − 11 ± 3 | − 6 ± 3* | − 6 ± 4* | |
| Stroke volume index (mL/m2) | 14 ± 4 | 10 ± 4* | 8 ± 4* | |
| Ejection fraction (%) | 12 ± 3 | 9 ± 3* | 8 ± 3* | |
| Cardiac output index (L/min/m2) | 6.7 ± 2.0 | 5.6 ± 1.3* | 4.7 ± 1.6*† | |
| Global longitudinal strain (%) | − 7.4 ± 2.1 | − 5.0 ± 2.0* | − 4.6 ± 2.5* | |
| Resting arterial oxygen saturation (%) | – | 98 ± 2 | 97 ± 2 | 0.357 |
| Peak arterial oxygen saturation (%) | – | 94 ± 2 | 96 ± 2 | 0.080 |
| Peak heart rate (bpm) | – | 161 ± 14 | 166 ± 12 | 0.110 |
| Peak power output (watts) | – | 165 ± 30 | 132 ± 31 | |
| Peak oxygen consumption (L/min) | – | 2.13 ± 0.41 | 1.69 ± 0.37 | |
| Peak oxygen consumption (mL/kg/min) | – | 29.5 ± 7.7 | 23.1 ± 7.5 | |
| Peak respiratory exchange ratio | – | 1.27 ± 0.08 | 1.29 ± 0.09 | 0.600 |
| Arteriovenous oxygen difference (mL/100 mL, impedance-derived) | – | 16.4 ± 3.6 | 15.2 ± 3.9 | 0.054 |
*Statistically different from young controls at p ≤ 0.05; † Statistically different from matched controls at p ≤ 0.05;– denotes data not collected in this group.
Figure 3Bioelectrical impedance cardiography data for cycle ergometer graded exercise test in breast cancer survivors (n = 16), age- and body mass index-matched non-cancer controls (n = 16). Stroke volume and cardiac output are normalized to body surface area. *Difference between groups at p ≤ 0.05.
Figure 4Predictors of peak volume of oxygen consumption (VO2) among anthracycline-treated breast cancer survivors and age- and body mass index-matched non-cancer controls. Trend line colors match included data. Both VO2 and volumes are normalized to body weight (kg) to standardize units.
Predictors of relative VO2peak (mL/kg/min) for breast cancer and matched controls combined (n = 32) with adjustment for group.
| Variables differing by group: | P-value: group interaction | ß (95% CI) for breast cancer | R2 (%) |
|---|---|---|---|
| Peak global longitudinal strain (%) | − 2.5 (− 3.8, − 1.1) | 45 | |
| Myocardial T1 time (ms) | − 0.19 (− 0.29, − 0.08) | 46 | |
| Thigh muscle fat fraction (%) | − 0.57 (− 0.83, − 0.32) | 68 |
Bolding indicates significance.
ß unstandardized beta coefficient, CI confidence interval, R coefficient of variation.